Drug Type CAR-T |
Synonyms induced pluripotent stem cell (iPSC) AlloCAR™ therapy, Solid & hematologic malignancies(Notch) |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization Notch Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | CA | Notch Therapeutics, Inc.Startup | 10 May 2024 |
Solid tumor | Preclinical | CA | Notch Therapeutics, Inc.Startup | 10 May 2024 |